文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

美国 2016-2020 年诊断的原发性脑和其他中枢神经系统肿瘤 CBTRUS 统计报告。

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020.

机构信息

Central Brain Tumor Registry of the United States, Hinsdale, IL, USA.

Department of Neurosurgery, Duke University School of Medicine, Durham, NC, USA.

出版信息

Neuro Oncol. 2023 Oct 4;25(12 Suppl 2):iv1-iv99. doi: 10.1093/neuonc/noad149.


DOI:10.1093/neuonc/noad149
PMID:37793125
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10550277/
Abstract

The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention and the National Cancer Institute, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous CBTRUS reports in terms of completeness and accuracy. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 24.83 per 100,000 population (malignant AAAIR=6.94 and non-malignant AAAIR=17.88). This overall rate was higher in females compared to males (27.85 versus 21.62 per 100,000) and non-Hispanic persons compared to Hispanic persons (25.24 versus 22.61 per 100,000). Gliomas accounted for 26.3% of all tumors. The most commonly occurring malignant brain and other CNS histopathology was glioblastoma (14.2% of all tumors and 50.9% of all malignant tumors), and the most common predominantly non-malignant histopathology was meningioma (40.8% of all tumors and 56.2% of all non-malignant tumors). Glioblastomas were more common in males, and meningiomas were more common in females. In children and adolescents (ages 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.13 per 100,000 population. There were 86,030 deaths attributed to malignant brain and other CNS tumors between 2016 and 2020. This represents an average annual mortality rate of 4.42 per 100,000 population and an average of 17,206 deaths per year. The five-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 35.7%, for a non-malignant brain and other CNS tumor the five-year relative survival rate was 91.8%.

摘要

美国中央脑肿瘤登记处(CBTRUS)与疾病控制与预防中心和国家癌症研究所合作,是美国最大的专注于原发性脑肿瘤和其他中枢神经系统(CNS)肿瘤的基于人群的登记处,代表了整个美国人口。本报告包含了最新的基于人群的原发性脑肿瘤数据,在完整性和准确性方面超过了 CBTRUS 的所有先前报告。所有比率均使用 2000 年美国标准人口进行年龄调整,并以每 10 万人为单位呈现。所有恶性和非恶性脑和其他 CNS 肿瘤的平均年年龄调整发病率(AAAIR)为 24.83/10 万人(恶性 AAAIR=6.94,非恶性 AAAIR=17.88)。女性的总体发病率高于男性(每 10 万人 27.85 比 21.62),非西班牙裔人口高于西班牙裔人口(每 10 万人 25.24 比 22.61)。神经胶质瘤占所有肿瘤的 26.3%。最常见的恶性脑和其他 CNS 组织病理学是胶质母细胞瘤(占所有肿瘤的 14.2%,所有恶性肿瘤的 50.9%),最常见的主要非恶性组织病理学是脑膜瘤(占所有肿瘤的 40.8%,所有非恶性肿瘤的 56.2%)。胶质母细胞瘤在男性中更为常见,脑膜瘤在女性中更为常见。在儿童和青少年(0-19 岁)中,所有原发性脑和其他 CNS 肿瘤的发病率为 6.13/10 万人。2016 年至 2020 年期间,有 86030 人死于恶性脑和其他 CNS 肿瘤。这代表平均每年每 10 万人中有 4.42 人死亡,平均每年有 17206 人死亡。恶性脑和其他 CNS 肿瘤诊断后的五年相对生存率为 35.7%,非恶性脑和其他 CNS 肿瘤的五年相对生存率为 91.8%。

相似文献

[1]
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020.

Neuro Oncol. 2023-10-4

[2]
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019.

Neuro Oncol. 2022-10-5

[3]
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021.

Neuro Oncol. 2024-10-6

[4]
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.

Neuro Oncol. 2021-10-5

[5]
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.

Neuro Oncol. 2019-11-1

[6]
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.

Neuro Oncol. 2020-10-30

[7]
The Central Brain Tumor Registry of the United States Histopathological Grouping Scheme Provides Clinically Relevant Brain and Other Central Nervous System Categories for Cancer Registry Data.

J Registry Manag. 2022

[8]
CBTRUS Statistical Report: American Brain Tumor Association & NCI Neuro-Oncology Branch Adolescent and Young Adult Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020.

Neuro Oncol. 2024-5-6

[9]
Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians.

Neurooncol Pract. 2022-2-22

[10]
Capturing evolving definitions of 12 select rare CNS tumors: a timely report from CBTRUS and NCI-CONNECT.

J Neurooncol. 2023-11

引用本文的文献

[1]
Progenitor cells, microglia, and non-coding RNAs: Orchestrators of glioblastoma pathogenesis and therapeutic resistance.

Noncoding RNA Res. 2025-8-5

[2]
Multiparametric MRI for differential diagnosis of primary central nervous system lymphoma and atypical glioblastoma: an analysis incorporating DWI, DCE-MRI, and contrast agent preload DSC-PWI.

BMC Med Imaging. 2025-8-25

[3]
DNA methylation analysis reveals an epigenetic signature distinctive of high-grade oligodendroglioma.

Acta Neuropathol. 2025-8-23

[4]
Quantitative assessment of the associations between MTR and MTRR gene polymorphisms and glioma risk.

Discov Oncol. 2025-8-23

[5]
MRI-defined patterns of infiltration and outcome in patients with glioblastoma.

Neurooncol Adv. 2025-7-11

[6]
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma.

Neurooncol Adv. 2025-7-18

[7]
Effects of re-challenge with temozolomide in grade 2/3 IDH mutant gliomas at first progression.

J Neurooncol. 2025-8-20

[8]
Attention-based deep learning network for predicting World Health Organization meningioma grade and Ki-67 expression based on magnetic resonance imaging.

Eur Radiol. 2025-8-20

[9]
Pediatric low-grade brainstem glioma: a review of current diagnosis and treatment paradigms in the molecular era.

Childs Nerv Syst. 2025-8-18

[10]
Reirradiation of recurrent glioblastoma: Results from a single-center retrospective cohort study.

Clin Transl Radiat Oncol. 2025-8-8

本文引用的文献

[1]
The Central Brain Tumor Registry of the United States Histopathological Grouping Scheme Provides Clinically Relevant Brain and Other Central Nervous System Categories for Cancer Registry Data.

J Registry Manag. 2022

[2]
Complete prevalence of primary malignant and nonmalignant brain tumors in comparison to other cancers in the United States.

Cancer. 2023-8-15

[3]
Cancer statistics, 2023.

CA Cancer J Clin. 2023-1

[4]
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019.

Neuro Oncol. 2022-10-5

[5]
CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.

Neuro Oncol. 2022-9-6

[6]
Aligning the Central Brain Tumor Registry of the United States (CBTRUS) histology groupings with current definitions.

Neurooncol Pract. 2022-3-24

[7]
Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.

Neuro Oncol. 2022-11-2

[8]
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

Neuro Oncol. 2021-8-2

[9]
An updated histology recode for the analysis of primary malignant and nonmalignant brain and other central nervous system tumors in the Surveillance, Epidemiology, and End Results Program.

Neurooncol Adv. 2020-12-8

[10]
Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma.

Neurooncol Pract. 2019-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索